arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

UNITED THERAPEUTICS Corp

UTHR
$538.83 ▲ +6.15 (+1.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
71 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

UNITED THERAPEUTICS Corp shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $23.4B
Dividend Yield
Revenue Growth -1.6%
Op. Margin 41.7%
ROIC 4.8%
FCF / Share $8.33
Trailing P/E 85.3x
Price / Book 3.9x
FCF Yield 1.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$781.50M
↓ -1.6%
Net Income Profit after all expenses
$274.90M
↓ -14.7%
Operating Margin Operating profit as % of sales
41.7%
↓ -7.6% 96th
FCF / Share Free cash flow per share
$8.33
↓ -3.1%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
96
Returns
85
Financial Health
95
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 71 quarters